Veterinary and Feed Additives API, Complete Buyers Guide

China is the world's largest producer and exporter of veterinary active pharmaceutical ingredients (APIs) and feed additives, supplying an estimated 60% or more of the global market. For procurement managers, regulatory specialists, and quality assurance professionals sourcing veterinary drug raw materials from China, understanding the product landscape, regulatory frameworks, and supplier evaluation criteria is essential for secure and compliant procurement in 2026.

1. Overview of Veterinary and Feed Additives API Market

The global animal health market surpassed USD 45 billion in 2025, with the veterinary API segment representing a substantial and growing portion. China's role in this market has expanded steadily over the past two decades, driven by large-scale fermentation capacity, integrated chemical synthesis infrastructure, and cost advantages in raw material supply chains. Major production clusters are concentrated in Shandong, Hebei, Jiangsu, Zhejiang, and Inner Mongolia, each specializing in different product categories ranging from antibiotic fermentation to chemical synthesis of antiparasitics.

Several structural trends are reshaping the veterinary API sourcing landscape. Consolidation among Chinese manufacturers has concentrated production of key molecules among fewer but larger and better-regulated facilities. Environmental enforcement in China has raised compliance costs, reducing the number of smaller, less-regulated producers and improving overall supply quality. The shift toward antibiotic-free production systems in the EU and North America is reshaping demand patterns, with growth in anticoccidials, antiparasitics, and feed additives offsetting reduced demand for antibiotic growth promoters. For buyers, these trends mean that China remains the dominant source for veterinary APIs, but supplier qualification and regulatory due diligence have become more important than ever.

2. Key Product Categories

2.1 Antibiotics: Spectinomycin, Lincomycin, Amoxicillin, Tylosin

Veterinary antibiotics represent the largest category of APIs sourced from China. Spectinomycin hydrochloride, used primarily in combination with lincomycin for poultry chronic respiratory disease (CRD), is produced through fermentation by several Chinese manufacturers holding US FDA Veterinary Master Files and CEP certifications. Lincomycin hydrochloride is another fermentation-derived antibiotic with broad applications in swine dysentery and poultry necrotic enteritis. Chinese production of lincomycin is concentrated in a small number of GMP-certified facilities, and supply can be tight during peak demand seasons.

Amoxicillin trihydrate, a semi-synthetic penicillin used across swine, poultry, and aquaculture, is one of the highest-volume veterinary antibiotics sourced from China. Chinese manufacturers operate at significant scale, with several facilities holding EU GMP certification. Tylosin tartrate and tilmicosin phosphate are macrolide antibiotics produced by fermentation; they are extensively used in swine and poultry for respiratory and enteric infections. Key producing regions for these antibiotics include Shandong, Hebei, and Ningxia, where fermentation infrastructure is well established.

2.2 Antiparasitics: Fenbendazole, Albendazole, Ivermectin, Toltrazuril

Antiparasitic APIs form the second-largest category sourced from China. Fenbendazole and albendazole, both benzimidazole anthelmintics, are used across ruminants, swine, and poultry for gastrointestinal nematode control. Chinese manufacturers produce these APIs at scale using well-established synthetic routes. Ivermectin, a macrocyclic lactone produced by fermentation of Streptomyces avermitilis, is one of the most widely used antiparasitics globally, with applications in cattle, swine, sheep, and companion animals. China accounts for a significant share of global ivermectin API production.

Toltrazuril, a triazinetrione anticoccidial used primarily in poultry and swine, has seen growing demand as intensive livestock production expands in emerging markets. Chinese toltrazuril manufacturers have invested in capacity expansion in recent years, and several facilities now hold CEP certifications for the European market.

2.3 Coccidiostats: Diclazuril, Halquinol

Coccidiostats are a specialized category of veterinary APIs used to control coccidiosis, a parasitic disease of significant economic importance in poultry production. Diclazuril, a benzeneacetonitrile derivative, is a potent and widely used anticoccidial with activity against both sexual and asexual stages of Eimeria species. Chinese production of diclazuril serves both the domestic market (China is the world's largest poultry producer) and export markets.

Halquinol, a chlorinated hydroxyquinoline, combines antibacterial, antifungal, and anticoccidial activity. It is used in poultry, swine, and aquaculture. Chinese manufacturers produce halquinol at competitive prices, and the product has seen steady demand growth as an alternative to ionophore coccidiostats.

2.4 Anti-inflammatories and Others

Beyond antibiotics, antiparasitics, and coccidiostats, Chinese manufacturers supply a range of additional veterinary APIs. Anti-inflammatory agents such as flunixin meglumine, used in cattle and swine for pain and inflammation management, and dexamethasone sodium phosphate, a corticosteroid with broad veterinary applications, are produced by multiple Chinese facilities. Enrofloxacin and its active metabolite ciprofloxacin remain important fluoroquinolone antibiotics in veterinary medicine, particularly in poultry and aquaculture, although regulatory restrictions on fluoroquinolone use in food-producing animals are tightening in several major markets. Doxycycline hyclate and florfenicol round out the portfolio of high-volume veterinary antibiotics sourced from China.

3. Regulatory Landscape for Veterinary APIs

3.1 VICH Guidelines for Veterinary Medicinal Products

VICH (International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products) is the veterinary equivalent of ICH for human pharmaceuticals. Established in 1996, VICH brings together regulatory authorities and industry associations from the EU, US, Japan, and observer countries including China, to harmonize technical requirements for veterinary product registration. VICH guidelines cover quality (chemistry and manufacturing), safety (target animal safety, consumer safety, environmental safety), and efficacy. For buyers sourcing veterinary APIs, understanding which VICH guidelines the supplier operates under provides a baseline for quality expectations. Key VICH quality guidelines relevant to API procurement include GL1 (validation of analytical procedures), GL10 (impurities in new veterinary drug substances), and GL11 (impurities in new veterinary medicinal products).

3.2 FDA-CVM: Center for Veterinary Medicine Requirements

The FDA Center for Veterinary Medicine (CVM) regulates veterinary APIs intended for use in food-producing animals in the United States. A Veterinary Master File (VMF) is the veterinary equivalent of a human drug DMF. A Type II VMF contains confidential detailed information about the manufacturing facility, production process, and quality controls for a veterinary API. For example, KingWish's spectinomycin hydrochloride holds FDA VMF 005884, which means the CVM has reviewed and accepted the filing. For buyers intending to use a veterinary API in a US-registered animal drug product, confirming that the API manufacturer holds an active VMF and has passed FDA inspection is a critical step in supplier qualification. Buyers should also verify whether the facility appears in the FDA warning letter database or has a history of import alerts.

3.3 EU Regulation 2019/6 on Veterinary Medicinal Products

EU Regulation 2019/6, which came into full effect in January 2022, represents the most significant overhaul of EU veterinary medicines legislation in decades. Key provisions affecting API procurement include stricter requirements for API GMP compliance (the API manufacturer must hold a GMP certificate issued by an EU competent authority or a recognized equivalent), enhanced pharmacovigilance obligations, and new restrictions on the use of certain antimicrobials in food-producing animals. For API sourced from China for use in EU-registered veterinary medicinal products, a CEP (Certificate of Suitability to the European Pharmacopoeia) is often the preferred route to demonstrate compliance. Several Chinese veterinary API manufacturers now hold CEPs for products including spectinomycin, ivermectin, and toltrazuril.

3.4 China's Veterinary Drug GMP Standards

China's Ministry of Agriculture and Rural Affairs (MARA) enforces Veterinary Drug GMP standards that apply to all domestic manufacturers of veterinary APIs. The current standard (2020 revision) aligns substantially with international GMP expectations under VICH and includes requirements for quality management, personnel, premises and equipment, documentation, production, quality control, and self-inspection. Facilities that meet China Veterinary GMP standards are listed on the MARA public database. While China Veterinary GMP certification alone may not be sufficient for regulated markets requiring EU GMP or FDA inspection, it provides a baseline quality assurance framework and confirms that the facility operates under regulatory oversight. Buyers should verify that a supplier's China Veterinary GMP certificate is current, product-specific, and issued for the actual production site.

4. Quality Standards: Vet API vs Human Pharma API

Veterinary APIs and human pharmaceutical APIs share many of the same quality principles, but there are important differences that buyers must understand. The fundamental quality standard for both is ICH Q7 (GMP for Active Pharmaceutical Ingredients). However, regulatory expectations for veterinary APIs differ from human APIs in several key areas.

Purity and impurity profiles: Veterinary APIs may have different purity requirements than human-grade equivalents. For example, a veterinary-grade antibiotic may be supplied at 90–95% potency on an anhydrous basis, whereas the human-grade version of the same molecule may require >98%. The impurity profile specification also differs; certain impurities that are tightly controlled in human APIs may have higher allowable limits or may not be specified at all in veterinary monographs. Buyers must verify which pharmacopoeia standard (USP veterinary monograph, EP veterinary monograph, or Chinese Veterinary Pharmacopoeia) applies to their procurement.

GMP rigor: While ICH Q7 applies to both human and veterinary APIs, the depth and frequency of regulatory inspection differ. A human API facility holding an FDA NAI classification and multiple successful inspections operates under more intensive regulatory scrutiny than a typical veterinary API facility. Dedicated veterinary API manufacturers may operate at GMP levels that meet veterinary regulatory expectations but fall short of the documentation and validation rigor expected for human pharmaceuticals. Buyers who require veterinary APIs for use in products destined for highly regulated markets (EU, US, Japan) should prioritize suppliers with EU GMP certification, CEP, or FDA VMF/inspection history, rather than relying solely on China Veterinary GMP certification.

5. How to Evaluate Veterinary API Suppliers in China

Evaluating a Chinese veterinary API supplier requires a systematic approach that covers regulatory status, quality system maturity, and commercial reliability. The following framework provides a structured methodology.

Step 1: GMP verification. Request the current GMP certificate. Confirm the issuing authority, the facility name and address matching the actual production site, and the product scope. For facilities targeting regulated markets, verify EU GMP certification through the EudraGMDP database or FDA inspection classification through the FDA Data Dashboard.

Step 2: VMF/DMF and CEP checking. For US-bound APIs, verify the VMF/DMF status through the FDA database. Confirm whether the VMF is "active" and whether the facility has been inspected. For EU-bound APIs, verify the CEP validity through the EDQM Certification database.

Step 3: Audit the facility. A quality audit (on-site or remote) should cover the quality management system, production equipment and maintenance, QC laboratory capabilities, supply chain traceability for starting materials and key intermediates, batch record review, and deviation/CAPA management. Pay particular attention to cleaning validation, especially if the facility produces multiple veterinary APIs on shared equipment and cross-contamination is a risk.

Step 4: Request samples and review documentation. An evaluation sample (typically 100–500 g for veterinary APIs) with a complete Certificate of Analysis allows buyers to conduct independent testing and verify the supplier's claimed specifications. Review the CoA against the relevant pharmacopoeia monograph and pay attention to batch-to-batch consistency.

Step 5: Check commercial references. Ask the supplier for references from existing customers and, where possible, verify those references independently. Consistent supply, on-time delivery, and responsive communication are as important as regulatory and quality credentials.

6. Top 10 Most-Sourced Veterinary APIs from China

The following table lists the ten most commonly sourced veterinary APIs from China, with their CAS numbers, categories, target species, and key indications. These products represent the core portfolio for most veterinary API importers and distributors.

7. Feed Additives: Vitamins, Amino Acids and Growth Promoters

Feed additives represent a distinct and equally important category in the animal health supply chain. Unlike veterinary APIs, which are pharmacologically active drug substances requiring prescription or veterinary oversight, feed additives are incorporated into animal feed to improve nutritional value, enhance growth performance, or maintain feed quality. China is the world's largest producer and exporter of several key feed additives.

Vitamins: Vitamin E (alpha-tocopherol acetate) is one of the highest-volume feed-grade vitamins produced in China, used as an antioxidant and immune function enhancer across all livestock species. Vitamin C (ascorbic acid), produced primarily through fermentation by Chinese manufacturers, is used in poultry and aquaculture for stress management and immune support. B-complex vitamins including B1 (thiamine), B2 (riboflavin), B6 (pyridoxine), and B12 (cyanocobalamin) are also produced at scale in China, with several facilities holding FAMI-QS certification for feed additive quality.

Amino acids: Lysine HCl, methionine, threonine, and tryptophan are essential amino acids produced through fermentation by large-scale Chinese manufacturers. These products are used in swine and poultry feed formulations to optimize protein utilization and growth performance. Chinese lysine production capacity is among the largest globally, and the sector has undergone significant consolidation, with a small number of major producers dominating supply.

Other feed additives: Choline chloride, betaine, and organic acids (citric acid, formic acid) produced in China are widely used in animal nutrition globally. Chinese manufacturers also produce a range of mineral supplements and enzyme preparations for feed applications. For feed additive procurement, FAMI-QS certification has become the de facto quality standard, and buyers should prioritize suppliers holding this certification alongside ISO 22000 or GMP+ for feed safety assurance.

8. Case Study: Poultry CRD Treatment Supply Chain

Chronic Respiratory Disease (CRD) in poultry, caused primarily by Mycoplasma gallisepticum, is one of the most economically significant diseases in global poultry production. The standard treatment protocol in many markets combines spectinomycin hydrochloride and lincomycin hydrochloride in a 2:1 ratio (Spec+Linco). The following case illustrates how a typical supply chain for these APIs operates.

A South American poultry integrator with 5 million broilers requires a reliable supply of Spec+Linco for CRD treatment. The integrator's regulatory requirements specify that both APIs must be sourced from facilities with active US FDA VMFs and must comply with the integrator's country-specific veterinary product registration requirements. After evaluating several suppliers, the integrator selects a combination of two Chinese manufacturers: one specializing in spectinomycin fermentation (holding VMF 005884) and one specializing in lincomycin fermentation, both with FDA inspection history.

Annual procurement volume is 2 metric tons of spectinomycin HCl and 1 metric ton of lincomycin HCl, shipped in quarterly lots of 500 kg and 250 kg respectively. The quarterly supply chain operates on a 12-week cycle: 4 weeks for documentation review and payment, 4 weeks for production or stock allocation, and 4 weeks for sea freight and customs clearance at the destination port. Each shipment includes a full documentation package comprising Certificate of Analysis, GMP certificate, VMF letter of authorization, and batch manufacturing record summary. The integrator maintains a 3-month safety stock to buffer against supply disruptions and conducts annual retained sample testing through an independent laboratory to verify ongoing quality consistency.

9. Working with KingWish for Veterinary API Procurement

KingWish supplies over 40 veterinary APIs and feed additives from GMP-certified manufacturing partners across China. With established relationships with manufacturers in Shandong, Hebei, Jiangsu, and Inner Mongolia, KingWish provides procurement consolidation, quality assurance, documentation management, and logistics coordination for international buyers. The company's Spectinomycin HCl holds FDA VMF 005884 and CEP 2024-135-REV 00, providing regulatory-ready documentation for buyers in US and EU markets.

For buyers who are new to veterinary API sourcing from China or who need to expand their supplier base, KingWish provides supplier qualification services including GMP verification, documentation review, and sample management. The company can accommodate evaluation orders as small as 1–5 kg for initial quality assessment, scaling up to full commercial volumes once the quality and regulatory requirements are confirmed. For buyers interested in understanding the end-to-end sourcing process, our companion guide How to Source Veterinary API from China provides a step-by-step procurement framework.

KingWish supplies veterinary APIs and feed additives across all major categories including antibiotics (spectinomycin, lincomycin, amoxicillin, tylosin, tilmicosin, doxycycline, florfenicol), antiparasitics (fenbendazole, albendazole, ivermectin, toltrazuril), coccidiostats (diclazuril, halquinol), and feed additives (vitamins, amino acids, choline chloride). Each shipment is accompanied by a full documentation package. Contact us for veterinary API specifications and a quotation tailored to your requirements and regulatory market.

Related Resources